From: Boris Nikolic < Sent: Monday, August 4, 2014 9:55 PM To: Jeffrey Epstein ([email protected]) Subject: you asked about FMI See article below and a table. The entire sector is down. A smaller companies and recent IPOs got it much wors= &nb=p; Email <http://www.geno=eweb.com/forward?path=node%2F1423236> &nb=p; Printer-friendly version <http://www.geno=eweb.com/print/1423236> &nb=p; RSS Feed <http://www.geno=eweb.com/newsletter/69886/feed> By a href="mailto:[email protected]"> a GenomeWeb staff reporter <=span> NEW YORK (GenomeWeb)— In July the stocks of com=anies operating in the omics research tools and molecular diagnostics spac=s returned almost all of their gains from June <http://www.genomeweb.com/omics-mdx-stocks-rise-5- percent-june-le=-exact-sciences-sequenom-pacbio-and-genm> as the GenomeWeb Daily News Index droppe= 5 percent month over month. In all, 25 of the 29 companies in the Index saw their =tock prices fall in July, with Pacific Biosciences (-26 percent), Cepheid =-21 percent), and GenMark Diagnostics (-21 percent) seeing the steepest de=lines. The biggest gainer during the month was Luminex, whose shares increased 6 percent. The GWDN Index's decline outpaced losses in t=e broader markets. The Dow Jones Industrial Average was down 2 percent mon=h over month, while the Nasdaq decreased a fraction of 1 percent, and the =asdaq Biotech Index dipped 2 percent. PacBio's drop follows a gain of nearly 25 percent in J=ne and was in spite of a reported 89 percent increase in revenues <http://www.genomeweb.com/sequencing/pacific-biosciences-q2-reven=es-climb-89-percent> for the second quarter. While the resul=s met the consensus analysts' estimate on the top line and exceeded expect=tions on the bottom line, its instrument bookings in the quarter fell shor= of expectations, leading to a 14 percent decrease in its share price the day after it released its Q2 fi=ancial results. Cepheid's drop also came in spite of a sharp